

Boardroom Media Release and Sales Update

Impression Healthcare Limited ('Impression', 'IHL' or the 'Company') is pleased to announce that CEO, Mr Joel Latham has undertaken a Boardroom Media interview, the key spoken highlights are as follows:

- The Company has ample cash reserves for the time being following record cash sales of \$513,000 for the March quarter; the receipt of the R&D rebate, and the receipt of the final tranche of the capital raise (announced 19 September 2018)
- Impression is in the process of arranging clinical trials with Cannvalate (announced 21 March 2019) and each of the trials will be commenced progressively as the materials are arranged.
- The three main objectives of the binding agreement with Cannvalate are:
 - Firstly, Cannvalate and Impression will conduct four separate phase 1 clinical trials for Obstructive Sleep Apnoea Syndrome (OSAS), Traumatic Brain Injury (TBI), Temporomandibular Joint (TMJ) Disorder and Periodontitis (Gum Disease);
 - Secondly, upon the achievement of successful clinical trials, Impression will commence the sale of up to four new products that correspond to the clinical trials through Cannvalate's fast-growing network of over 1000 prescribing doctors and 600 pharmacists; and,
 - Thirdly, Impression intends to sell medicinal cannabis oils through the Cannvalate network as a "generic" type product, as oils are the most prescribed product in the market today.
- The clinical trials will take about 90 days from the commencement date and it is conceivable that Impression will achieve sales resulting from the Cannvalate collaboration in the second half of 2019.
- The clinical trials will be led from the Swinburne University of Technology. The budget for the trials is in excess of \$3M, however, IHL's cash contribution is limited to \$80,000 (plus GST) per trial.
- IHL retains the intellectual property associated with the trials and successful clinical trials are the best way to capture the attention of the prescribing medical community.

The link to the Boardroom Media article is here:

<https://www.boardroom.media/broadcast/?eid=5ca2e4d1fd76da0f45bdc491>

About Impression Healthcare Limited (ASX: IHL)

Impression Healthcare Limited is an innovative healthcare company that sells customised oral devices both direct-to-the-consumer and via the Company's growing B2B preferred practitioner network of dentists. With its own laboratory in Victoria, Australia, Impression offers best-in-class teeth-protection and helps its customers to combat bruxism, snoring, mild-to-moderate sleep apnoea and teeth discolouration with custom-fitted oral devices.

Impression has broadened its commitment to disruption in the healthcare sector by progressing multiple opportunities in the field of medicinal cannabis. IHL has its licenses in place to import, export and distribute cannabis products. In March of 2019, Impression executed a binding collaboration with Cannvalate to undertake four medicinal cannabis clinical trials. Cannvalate is Australia's largest distributor of medicinal cannabis products.

IHL also has a collaboration agreement with leading US Cannabinoid therapeutics Company, AXIM Biotechnologies Incorporated; a license agreement for the production and distribution of Dronabinol in the USA, Canada, Australia and New Zealand; and also intends to distribute medicinal cannabis oils through the Cannvalate network of cannabis medicine prescribers throughout Australia.

Investors: investors@impression.healthcare

Website: www.impression.healthcare